Rock Creek Pharmaceuticals Inc. (fka RCPIQ)

[Buddhahead]

Qu Biologics Opens Clinical Trial Sites in Edmonton and Toronto for Crohn's Disease Clinical Trial in Market Wired, April 24, 2015

Press Release:
"Qu Biologics Inc., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore the body's normal immune function in the targeted diseased organ, announced today it has opened two new clinical trial sites in Edmonton, Alberta and Toronto, Ontario to enroll participants in its Crohn's disease clinical trial.
Qu Biologics' Crohn's disease clinical trial is a randomized, placebo-controlled research trial enrolling participants living with moderate-to-severe Crohn's disease. The trial involves the use of Qu Biologics' QBECO SSI, a novel immunotherapy treatment derived from components of inactivated E. coli bacteria, designed to stimulate an innate immune response in the gastrointestinal tract to reverse the underlying chronic inflammation related to Crohn's disease. The clinical trial takes place in Vancouver, Edmonton and Toronto.
Qu Biologics' CEO Dr. Hal Gunn commented, "Opening trial sites in Edmonton and Toronto allow participants from other provinces to access our clinical trial closer to home." He added, "These two new clinical trial sites will also help us accelerate our goal of completing trial enrollment by Q3 2015 and obtaining primary results by the end of the year."

Press release at:
http://www.marketwired.com/press-release/qu-biologics-opens-clinical-trial-sites-edmonton-toronto-crohns-disease-clinical-trial-2013286.htm